CION Ameerpet
Pancreatic Cancer · Neuroendocrine Tumours (PNET) · Reviewed by CION Oncologists
Somatostatin analogue therapy for PNETs — one injection, two different jobs
Most people meet this treatment as a monthly injection with a long name and very little explanation. It is the usual first systemic treatment for a well-differentiated pancreatic neuroendocrine tumour, and it is asked to do two separate jobs — settle hormone symptoms, and slow the tumour down.
- Not chemotherapy — a long-acting injection from a hormone-analogue class, usually given monthly.
- It is asked to do two jobs — settle hormone symptoms, and hold a well-differentiated tumour still.
- A receptor scan decides whether it fits — receptor-rich disease is what this class is built for.
- Feeling no different is normal — in a non-functioning tumour, an unchanged scan is the result you want.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Somatostatin-Analogue Therapy Actually Is
If you have been searching “somatostatin analogue pnet” since your appointment, you are looking for the treatment most people with a well-differentiated pancreatic neuroendocrine tumour are offered first. It is not chemotherapy. It is a long-acting injection, usually given once a month at a day-care visit, from a class of medicines that copies a hormone your own body already makes.
Somatostatin is a natural brake. Your body releases it in small amounts to quieten hormone release from the gut and the pancreas, and it disappears from the bloodstream within minutes — which is exactly what makes the natural hormone useless as a treatment. An analogue is a laboratory-made copy, built to survive far longer. Long enough that a single depot injection keeps working for weeks.
It works on a neuroendocrine tumour because the tumour cells usually keep the receptors the natural hormone was designed to land on. When the analogue binds to those somatostatin receptors, two things follow. Hormone release from the tumour falls, which is what settles the symptoms of a functioning PNET. And in well-differentiated, receptor-rich tumours the growth signal inside the cell is turned down as well, which is why the same injection is offered to people who have no hormone symptoms at all.
That single idea explains most of what follows: why a receptor scan is arranged before the first dose, why this class is usually chosen ahead of harder-hitting options, and why success is often a scan that shows nothing new rather than a tumour that shrinks. Where this treatment sits among all the other options is set out in how pancreatic neuroendocrine tumours are treated.
Did you know? NCCN publishes a separate guideline for neuroendocrine and adrenal tumours, distinct from its pancreatic adenocarcinoma guideline, and that document lists somatostatin-analogue-class therapy as a first-line systemic option in advanced, well-differentiated, somatostatin-receptor-positive disease — for two distinct purposes: controlling the hormone syndrome of a functioning tumour, and slowing tumour growth in its own right. Whether your tumour is the well-differentiated type this class is aimed at is decided by the WHO classification of neuroendocrine neoplasms, which your pathologist applies to the biopsy. Read together, those two documents are why the same monthly injection can be offered to one person for flushing and diarrhoea, and to another who feels completely well.
One injection, two jobs
What This Class of Treatment Is Actually Asked to Do
The same monthly injection is prescribed for two quite different reasons. Knowing which one applies to you changes what you should expect from it.
Hormone control
Settling a functioning tumour
Where a tumour is releasing hormone, the analogue turns the tap down. Flushing, loose stools, wheeze, reflux or low blood sugar episodes often ease within the first weeks — usually the fastest visible benefit.
Growth control
Slowing a tumour that causes no symptoms
In a non-functioning tumour the aim is different: hold the disease still. The measure of success is a scan that has not changed, which can feel anticlimactic and is in fact the whole point.
Receptor status
Why a receptor scan comes first
A DOTATATE PET shows which deposits carry somatostatin receptors. Receptor-rich disease is what this class is built for. That scan is coordinated with partner nuclear medicine centres, not performed in-house at CION.
Grade and differentiation
Aimed at well-differentiated disease
This class suits tumours the pathologist calls well differentiated, with a low proliferation index. Fast, poorly differentiated disease is treated differently, and being told so is not a setback — it is the plan being matched to the biology.
Not chemotherapy
What this treatment is not
It is not chemotherapy, and it is not the receptor-targeted radionuclide treatment sometimes discussed later. It does not cause hair loss, mouth ulcers or the blood-count crashes people associate with chemotherapy.
Sequence
It does not close doors
Starting here keeps the later options open — targeted oral therapy, chemotherapy where the grade calls for it, receptor-targeted radionuclide therapy at a partner unit, and surgery where it becomes possible.
Judged differently
The Same Injection, Two Different Measures of Success
People often judge this treatment against the wrong yardstick, then conclude it is not working when it is.
| What you are asking of it | When the job is hormone control | When the job is slowing the tumour |
|---|---|---|
| Who it is usually for | A functioning tumour that is producing a hormone syndrome. | A well-differentiated, receptor-positive tumour that is advancing or too widespread to remove. |
| What you should notice | Symptoms settling — fewer episodes, firmer stools, less flushing — often within the first weeks. | Usually nothing at all. Feeling no different is the expected experience, not a sign of failure. |
| How it is judged | Your own symptom record, alongside blood tests where the specific hormone can be measured. | Scans compared over time, each read against the previous one rather than in isolation. |
| How long it continues | For as long as it keeps symptoms controlled and you tolerate it. | For as long as scans stay stable and side effects stay manageable. |
| What a change looks like | Symptoms creeping back before the next injection is due, which prompts a review of dose or interval. | A new or growing deposit on a scan, which moves the conversation on to the next option. |
Bring the pathology report and the most recent scan report to the first appointment. Those two documents answer more about whether this class fits you than anything you will read online. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
One Injection, Two Very Different Jobs
Knowing which job yours is being asked to do changes what you should expect from it.
What actually happens
How Treatment Actually Runs, Month to Month
-
The pathology report is read properly
Grade, differentiation and whether the tumour is functioning are confirmed before anything is prescribed. This class is matched to the biology, not to the diagnosis alone.
In-house at CION -
Receptor status is established
A DOTATATE PET shows whether the disease carries the receptors this treatment depends on, and where every deposit sits. Without that answer, starting is guesswork.
Coordinated with partner nuclear medicine centres -
Baseline bloods, imaging and a symptom record
Blood tests, a pancreatic-protocol CT or MRI, and a written note of your current symptoms create the line that everything afterwards is measured against.
Ordered and reported in-house at CION -
The first injection
A long-acting depot given as a deep injection at a day-care visit, at whichever of our 35+ centres is nearest you. There is no drip and no admission, and you go home the same day.
In-house at CION -
Review between injections
Each visit checks the things this class actually causes — bowel habit, wind and cramping, blood sugar, gallbladder symptoms — and adjusts the supportive care around them.
In-house at CION -
Reassessment by scan
A pancreatic-protocol CT or MRI is repeated at planned intervals and read against the last one; where a repeat DOTATATE PET is needed, it is arranged at a partner nuclear medicine centre. If the picture changes, the plan moves on — the full range of PNET treatment options is set out separately.
CT and MRI reported in-house; repeat DOTATATE PET coordinated with partner centres; reviewed at the CION tumour board
Plainly stated
What CION Delivers, and What Is Coordinated
Your first consultation with us is free and lasts 45 minutes. It is a genuine reading of your reports with a medical oncologist, not a booking appointment.
Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: this treatment itself — the prescription, the injection at a day-care visit, and the monitoring around it. Also the other systemic options for neuroendocrine tumours, if and when they are needed; radiation where it is appropriate; the ordering and reporting of pancreatic-protocol CT, MRI and blood tests; genetic counselling where an inherited syndrome is suspected; nutrition and pancreatic enzyme support; pain relief, psycho-oncology and supportive care; and long-term follow-up. Pancreatic cancer treatment in Hyderabad explains how those services are organised across the network.
Coordinated with specialist HPB, gastroenterology, endoscopy and nuclear medicine partner centres, and may be billed there: the DOTATATE PET that decides whether this class suits you at all; PET-CT; endoscopic ultrasound with biopsy; all pancreatic surgery; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; and peptide receptor radionuclide therapy, which is given at a partner nuclear medicine unit. We arrange these, we sit in on the decisions, and we tell you in advance where each one happens and who invoices you. We do not describe them as our own scanners, theatre or endoscopy lists, because they are not.
The honest side of this class. The first weeks often bring loose stools, wind and cramping, because the same brake that quietens the tumour also slows the release of digestive enzymes; pancreatic enzyme support usually helps, and these effects tend to settle. Gallstones can form with longer use and are frequently silent, so we look for them rather than wait for pain. Blood sugar can move in either direction, which matters if you already have diabetes. The injection site can ache for a day or two. And there is the plain burden of a monthly appointment, which is better planned around work and travel than discovered afresh each month.
This page stays deliberately on the injection itself. If you want the wider picture around it, our complete guide to pancreatic cancer covers the disease as a whole, including how a neuroendocrine tumour differs from the commoner ductal type.
If you have been told to start a monthly injection and nobody has explained what it is being asked to do, bring the reports in and we will go through them line by line. Book a free consultation or call 1800 202 8726.
Take the next step
Ask What This Treatment Is Meant to Achieve
We walk this journey with you, with the time to explain what your own reports actually say.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Somatostatin-analogue therapy for PNETs - your questions answered
What does somatostatin-analogue therapy actually do?
It copies a hormone your body already makes, in a form built to last far longer. Most well-differentiated pancreatic neuroendocrine tumours keep the receptors that hormone lands on, and when the copy binds to them, two things happen. Hormone release from the tumour falls, which is what settles the flushing, loose stools or low blood sugar episodes of a functioning tumour. And the growth signal inside the tumour cell is turned down, which is why the same injection is offered to people who have no hormone symptoms at all. It is not chemotherapy, and it is not the receptor-targeted radionuclide treatment that is sometimes discussed later. It is usually the first systemic treatment tried, because it is generally well tolerated and it does not close off any of the options that come after it.
Why do I need a DOTATATE PET before starting?
Because this treatment only works on tumour cells that carry somatostatin receptors, and a scan is the only way to know whether yours do. A DOTATATE PET lights up receptor-rich disease and also shows where every deposit sits, which can change the plan on its own. If the scan shows little or no receptor uptake, starting this class would be treating hope rather than biology, and a different route is the honest recommendation. This scan is coordinated with partner nuclear medicine centres rather than performed at CION, so we arrange it, tell you where it happens, and tell you in advance that it may be billed there. The result is worth waiting for, and starting without it is guesswork.
What are the common side effects?
Most people tolerate this class well, but it is not free of effects. The first weeks often bring loose stools, wind and cramping, because the same brake that quietens the tumour also slows the release of digestive enzymes. Pancreatic enzyme support usually helps, and these effects tend to settle. Gallstones can form with longer use and are frequently silent, so we look for them rather than wait for pain. Blood sugar can move in either direction, which matters particularly if you already have diabetes. The injection site can ache for a day or two. What this class does not typically cause is hair loss, mouth ulcers or the blood-count crashes people associate with chemotherapy. Report any effect early, because most are managed by adjusting supportive care rather than by stopping treatment.
How will anyone know whether it is working?
It depends which job it is doing. If your tumour is functioning, you are the measurement: fewer flushing episodes, firmer stools, steadier blood sugar, less wheeze or reflux, judged against the symptom record made before you started. Where the specific hormone can be measured in blood, that trend is followed as well. If your tumour is non-functioning, the answer comes from scans compared over time rather than from how you feel, and the result you want is a scan that has not changed. Stability is a genuine success here, not a disappointing one. Shrinkage does happen, but it is not the usual aim of this class, and expecting it can make a good result feel like a bad one. Scans are repeated at planned intervals and always read against the previous one.
What happens if it stops holding the tumour?
At some point a scan may show change, and that is not a crisis or a failure of the treatment. It means the plan moves to its next step, which was thought about before you started. Depending on grade, receptor status and where the disease is, that step may be targeted oral therapy, chemotherapy where the grade calls for it, receptor-targeted radionuclide therapy at a partner nuclear medicine unit, a liver-directed treatment where the liver is the main problem, or surgery where it has become possible. Sometimes the analogue is continued alongside the next treatment, purely to keep hormone symptoms controlled. This is one reason the sequence matters, and why starting with a well-tolerated option that keeps the others available is a deliberate choice rather than caution.
What does CION do for this treatment, and what happens at the first visit?
The treatment itself is delivered in-house: the prescription, the injection at a day-care visit at whichever of our 35+ centres is nearest you, and the monitoring around it, alongside blood tests and scan reporting, nutrition and pancreatic enzyme support, pain relief, psycho-oncology and long-term follow-up. The DOTATATE PET that decides whether this class suits you, endoscopic ultrasound and biopsy, all pancreatic surgery, and receptor-targeted radionuclide therapy are coordinated with specialist partner centres and may be billed there, and we say so in advance rather than after the invoice. The first consultation is free and lasts 45 minutes. Bring the pathology report, the most recent scan report, and a list of your current symptoms and medicines. We read those with you, say plainly whether this class fits, and write down what happens next and when.
Medical disclaimer: This page explains what somatostatin-analogue-class therapy is and how it is used in pancreatic neuroendocrine tumours, and is reviewed by a CION medical oncologist with reference to NCCN guidance on neuroendocrine and adrenal tumours and the WHO classification of neuroendocrine neoplasms. It deliberately names no individual medicine and states no survival or response figure, because such figures describe groups rather than a person; whether this class suits you depends on your tumour's grade, differentiation, receptor status and extent, and must be decided with your treating team. Somatostatin-analogue-class therapy and the other systemic treatments for neuroendocrine tumours, radiation where appropriate, the ordering and reporting of CT, MRI and blood tests, genetic counselling, nutrition and pancreatic enzyme support, pain relief, psycho-oncology and long-term follow-up are delivered by CION; DOTATATE PET and PET-CT, endoscopic ultrasound and biopsy, all pancreatic surgery, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block and peptide receptor radionuclide therapy are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.